Identification of New CD36 Antagonists by Structure‐Based Virtual Screening
Chemical Biology & Drug Design · 2025
DOI: 10.1111/cbdd.70205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2025. Verfasst von Sandra L Guerrero-Rodríguez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Medicine, Universidad Nacional Autónoma de México, Mexico City, Mexico. Hauptthemen laut MEDLINE: CD36 Antigens. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Universidad Nacional Autónoma de México, Consejo Nacional de Humanidades, Ciencias y Tecnologías.
Abstract (Originalsprache)
CD36 is a transmembrane glycoprotein that facilitates the uptake of fatty acids and oxidized low‐density lipoproteins. CD36 is overexpressed in various types of cancer and CD36 + cancer cells display enhanced malignancy, including resistance to therapy and elevated stemness and metastatic ability. Thus, CD36 is a therapeutic target in cancer. This study aimed to discover new CD36 antagonists through virtual screening. We identified a druggable pocket in CD36 that is functionally relevant and serves as the binding site for reported antagonists. Consensus molecular docking of a chemical library containing over 25,000 drug‐like compounds identified 15 computational hits with structural diversity. Experimental evaluation of seven compounds revealed that compounds 8, 13, and 14 are novel inhibitors of CD36‐mediated palmitate and/or oxLDL uptake in cellular models. Compound 14 reduced the clonogenicity of HepG2 cells without impacting cell viability, showing that it modulates CD36‐triggered phenotypes associated with disease progression. Analysis of molecular interactions of compounds 8, 13, or 14 with CD36 by molecular dynamics simulations showed that the identified antagonists had stable binding and favorable binding energy, leading to distinct conformational states of the protein. These results support the use of the antagonists identified here as lead compounds for developing CD36‐targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Medicine, Universidad Nacional Autónoma de México, Mexico City, Mexico.
- Secretaría de Ciencia, Humanidades, Tecnología e Innovación, Mexico City, México.
- Graduate Program in Biochemical Sciences, Universidad Nacional Autónoma de México, Mexico City, Mexico.
- Department of Physiology, School of Medicine, Universidad Nacional Autónoma de México, Mexico City, Mexico.
- Department of Biochemistry, School of Medicine, Universidad Nacional Autónoma de México, Mexico City, Mexico.
ORCID-Profile: Luis Córdova-Bahena, Marco A Velasco-Velázquez
Förderung
- Universidad Nacional Autónoma de México
- Consejo Nacional de Humanidades, Ciencias y Tecnologías
Zitieren
APA
Guerrero-Rodríguez, S. L., Córdova-Bahena, L., Cortés-Mendoza, F., Ruiz-Moreno, A. J., Mata-Cruz, C., Velázquez-Paniagua, M., Salinas-Jazmín, N., González-Andrade, M., & Velasco-Velázquez, M. A. (2025). Identification of New CD36 Antagonists by Structure‐Based Virtual Screening. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70205
Vancouver
Guerrero-Rodríguez SL, Córdova-Bahena L, Cortés-Mendoza F, Ruiz-Moreno AJ, Mata-Cruz C, Velázquez-Paniagua M, et al. Identification of New CD36 Antagonists by Structure‐Based Virtual Screening. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70205
BibTeX
@article{GuerreroRodrguez2025,
author = {Guerrero-Rodríguez, Sandra L and Córdova-Bahena, Luis and Cortés-Mendoza, Fabiola and Ruiz-Moreno, Angel J and Mata-Cruz, Cecilia and Velázquez-Paniagua, Mireya and Salinas-Jazmín, Nohemí and González-Andrade, Martín and Velasco-Velázquez, Marco A},
title = {Identification of New CD36 Antagonists by Structure‐Based Virtual Screening},
journal = {Chemical Biology & Drug Design},
year = {2025},
doi = {10.1111/cbdd.70205}
}
EUVIMED